RAPT Therapeutics, Inc. (RAPT)

Market Cap	488.36M
Revenue (ttm)	n/a
Net Income (ttm)	-106.49M
Shares Out	16.54M
EPS (ttm)	-6.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	555,135
Open	29.75
Previous Close	30.00
Day's Range	28.87 - 30.00
52-Week Range	5.67 - 42.39
Beta	0.23
Analysts	Strong Buy
Price Target	46.75 (+58.31%)
Earnings Date	Nov 11, 2025

About RAPT

RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX47...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 31, 2019
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: RAPT
• Website: https://www.rapt.com

Analyst Summary

According to 8 analysts, the average rating for RAPT stock is "Strong Buy." The 12-month stock price target is $46.75, which is an increase of 58.31% from the latest price.

Price Target

$46.75

(58.31% upside)

Analyst Consensus: Strong Buy